Exelixis Wins Appeal in Patent Case Against MSN Laboratories

MT Newswires Live

Yesterday

Exelixis (EXEL) said Monday that the US Court of Appeals for the Federal Circuit has affirmed a key portion of the 2024 judgment of the US District Court for the District of Delaware in its favor in the lawsuit Exelixis vs. MSN Laboratories.

The Federal Circuit's decision upheld the validity of three patents covering the crystalline malate salt of cabozantinib, preserving market exclusivity for Exelixis' cabozantinib, and dismissed the appeal regarding the validity dispute over another Exelixis patent covering low-impurity cabozantinib formulations, ruling the matter moot.

Given the decision, the earliest that MSN may be permitted to commercially launch its proposed generic product in the US is Jan. 15, 2030, subject to any additional appeals or regulatory exclusivity, the company added.

Price: 54.35, Change: -0.10, Percent Change: -0.18

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://au1.tigerplaytime.com/news/2664000055"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2664000055\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2664000055?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-09-01 03:25","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2664000055","market":"nz","top_or_hot":-1,"title":"Exelixis Wins Appeal in Patent Case Against MSN Laboratories","media":"MT Newswires Live","content":"<html><body><p> Exelixis (EXEL) said Monday that the US Court of Appeals for the Federal Circuit has affirmed a key portion of the 2024 judgment of the US District Court for the District of <a href=\"https://laohu8.com/S/VMM\">Delaware</a> in its favor in the lawsuit Exelixis vs. MSN Laboratories.</p><p>The Federal Circuit's decision upheld the validity of three patents covering the crystalline malate salt of cabozantinib, preserving market exclusivity for Exelixis' cabozantinib, and dismissed the appeal regarding the validity dispute over another Exelixis patent covering low-impurity cabozantinib formulations, ruling the matter moot.</p><p>Given the decision, the earliest that MSN may be permitted to commercially launch its proposed generic product in the US is Jan. 15, 2030, subject to any additional appeals or regulatory exclusivity, the company added.</p><p>Price: 54.35, Change: -0.10, Percent Change: -0.18</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Exelixis Wins Appeal in Patent Case Against MSN Laboratories</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nExelixis Wins Appeal in Patent Case Against MSN Laboratories\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-09-01 03:25</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Exelixis (EXEL) said Monday that the US Court of Appeals for the Federal Circuit has affirmed a key portion of the 2024 judgment of the US District Court for the District of <a href=\"https://laohu8.com/S/VMM\">Delaware</a> in its favor in the lawsuit Exelixis vs. MSN Laboratories.</p><p>The Federal Circuit's decision upheld the validity of three patents covering the crystalline malate salt of cabozantinib, preserving market exclusivity for Exelixis' cabozantinib, and dismissed the appeal regarding the validity dispute over another Exelixis patent covering low-impurity cabozantinib formulations, ruling the matter moot.</p><p>Given the decision, the earliest that MSN may be permitted to commercially launch its proposed generic product in the US is Jan. 15, 2030, subject to any additional appeals or regulatory exclusivity, the company added.</p><p>Price: 54.35, Change: -0.10, Percent Change: -0.18</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2664000055","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2664000055","pubTimestamp":1788204310,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Exelixis  said Monday that the US Court of Appeals for the Federal Circuit has affirmed a key portion of the 2024 judgment of the US District Court for the District of Delaware in its favor in the lawsuit Exelixis vs. MSN Laboratories.The Federal Circuit's decision upheld the validity of three patents covering the crystalline malate salt of cabozantinib, preserving market exclusivity for Exelixis' cabozantinib, and dismissed the appeal regarding the validity dispute over another Exelixis patent covering low-impurity cabozantinib formulations, ruling the matter moot.Given the decision, the earliest that MSN may be permitted to commercially launch its proposed generic product in the US is Jan. 15, 2030, subject to any additional appeals or regulatory exclusivity, the company added.Price: 54.35, Change: -0.10, Percent Change: -0.18","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","BK4532":"文艺复兴科技持仓","MSN":"Emerson Radio Corp","BK4078":"消费电子产品","EXEL":"伊克力西斯"},"translate_title":"Exelixis 赢得针对 MSN Laboratories 的专利诉讼","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MSN":1.5,"EXEL":1.5},"content_text":"Exelixis (EXEL) said Monday that the US Court of Appeals for the Federal Circuit has affirmed a key portion of the 2024 judgment of the US District Court for the District of Delaware in its favor in the lawsuit Exelixis vs. MSN Laboratories.The Federal Circuit's decision upheld the validity of three patents covering the crystalline malate salt of cabozantinib, preserving market exclusivity for Exelixis' cabozantinib, and dismissed the appeal regarding the validity dispute over another Exelixis patent covering low-impurity cabozantinib formulations, ruling the matter moot.Given the decision, the earliest that MSN may be permitted to commercially launch its proposed generic product in the US is Jan. 15, 2030, subject to any additional appeals or regulatory exclusivity, the company added.Price: 54.35, Change: -0.10, Percent Change: -0.18","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}